Solid lipid nanoparticles: the enhanced and targeted potential treatment of colorectal cancer

The third most frequently occurring disease in both men and women and the third leading cause of death globally is colorectal cancer (CRC). Standard chemotherapy drugs are used to target the particular part of the body affected by cancer. They act, in particular, on parts of cancer cells that make them different from healthy cells. Some of these drugs are presently used to treat advanced CRC. Several researchers have been studying solid lipid nanoparticles (SLNs) and their cytotoxicity over the last 2 decades, their detailed report signifying that the drug loading capacity potentially improved cytotoxicity and reduced the adverse effect of the free drug. Pharmaceutically, SLNs improved physicochemical properties and stability and enhanced the pharmacological properties of the drug. It has been validated as a potential carrier of the drug with delivery targeted at a particular area. The complications associated with chemodrugs are abnormal toxicity to tissues, poor stability, and targeting capabilities with a high prevalence of drug-resistant tumor cells, and these are overcome by delivering the drug using SLNs. Focusing on some particular human tissues, such as bone marrow and solid tumors, requires the fast ejection of colloidal particles by the macrophages of the Reticuloendothelial System (RES).